- Trials with a EudraCT protocol (48)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
48 result(s) found for: Lifestyle medicine.
Displaying page 1 of 3.
EudraCT Number: 2008-005892-83 | Sponsor Protocol Number: WCH/2008/001 | Start Date*: 2009-01-14 |
Sponsor Name:Epsom and St Helier University Hospitals NHS Trust | ||
Full Title: Does metformin improve pregnancy outcomes [ incidence of LGA (≥90% birth weight centile) babies onset of maternal Gestational Diabetes, hypertension, PET, shoulder dystocia, admission to SCBU) in o... | ||
Medical condition: Obesity in pregnancy. Obesity in pregnancy has been identified by Confidential Enquiry into Maternal And Child Health (CEMACH) (2008-2011) as a major health risk to mother and baby. | ||
Disease: | ||
Population Age: Adults | Gender: Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2008-007945-29 | Sponsor Protocol Number: BALAD | Start Date*: 2009-09-25 | |||||||||||
Sponsor Name:Institute of Cancer research and molecular medicine. | |||||||||||||
Full Title: Treatment of LADA . | |||||||||||||
Medical condition: Latent Autoimmune diabetes of the adult (LADA) is a form of diabetes where the onset of the diabetes starts after 30 years of age, there is presence of beta-cell directed antibodies (mostly anti-GA... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Ongoing) FI (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-001356-36 | Sponsor Protocol Number: 20131 | Start Date*: 2013-10-10 | |||||||||||
Sponsor Name:"G. d'Annunzio" University | |||||||||||||
Full Title: Effects of liraglutide or lifestyle counselling on subcutaneous adipose tissue and visceral adipose tissue distribution, circulating adipokine concentration, insulin sensitivity and beta-cell perfo... | |||||||||||||
Medical condition: Obesity with a diagnosis of impaired glucose tolerance (IGT) or impaired fasting glucose (IFG) or type 2 Diabetes Mellitus (T2DM) for less than 12 months, according to the American Diabetes Associa... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2009-015058-38 | Sponsor Protocol Number: OR09/9018 | Start Date*: 2010-10-22 |
Sponsor Name:University of Leeds | ||
Full Title: Improving the outcome for patients after osteoporotic femoral fractures | ||
Medical condition: OSTEOPOROTIC FEMORAL FRACTURE | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2011-006352-36 | Sponsor Protocol Number: VPN-10-18 | Start Date*: 2013-04-11 | ||||||||||||||||
Sponsor Name:Lithuanian University of Health Sciences, Endocrinology Department | ||||||||||||||||||
Full Title: Obesity in children and adolescents: complications, associated risks and early intervention (lifestyle changes and insulin sensitivity improving medicine (metformin) effectiveness and safety evalua... | ||||||||||||||||||
Medical condition: The aim of our study is to establish the effectivenes and safety of metformin use in pediatric obese population; to assess the prevalence of insulin resistance, metabolic syndrome, polycystic ovary... | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |||||||||||||||||
Trial protocol: LT (Completed) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-022384-35 | Sponsor Protocol Number: CCX114644 | Start Date*: 2011-02-02 | |||||||||||
Sponsor Name:GlaxoSmithKline Research & Development Ltd | |||||||||||||
Full Title: An Open-Label Extension Study to Assess the Safety of GSK1605786A in Subjects with Crohn’s Disease | |||||||||||||
Medical condition: Subjects with Crohn’s Disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) BE (Prematurely Ended) SE (Prematurely Ended) GB (Prematurely Ended) CZ (Prematurely Ended) DK (Prematurely Ended) HU (Prematurely Ended) GR (Prematurely Ended) AT (Completed) PL (Prematurely Ended) ES (Prematurely Ended) PT (Prematurely Ended) EE (Completed) IT (Completed) SK (Completed) BG (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-002634-24 | Sponsor Protocol Number: MultipleMS | Start Date*: 2017-09-29 |
Sponsor Name:Karolinska Institutet | ||
Full Title: MultipleMS – Multiple-omics approach to accelerate personalised medicine in a prospective cohort of newly diagnosed MS and CIS patients. | ||
Medical condition: Newly diagnosed patients with Clinically Isolated Syndrome (CIS) and multiple sclerosis (MS) -both relapsing remitting and primary progressive) | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: SE (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2020-005187-63 | Sponsor Protocol Number: FM101-CTP2-001 | Start Date*: 2021-04-14 | ||||||||||||||||
Sponsor Name:Future Medicine Co., Ltd. | ||||||||||||||||||
Full Title: A Randomized Phase 2a Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of FM101 in Adults with Nonalcoholic Fatty Liver Disease (NAFLD) or Nonalcoholic Steatohepatitis (NASH) | ||||||||||||||||||
Medical condition: Nonalcoholic Fatty Liver Disease (NAFLD) or Nonalcoholic Steatohepatitis (NASH) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: HU (Prematurely Ended) ES (Prematurely Ended) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-002938-20 | Sponsor Protocol Number: 13031 | Start Date*: 2013-11-08 |
Sponsor Name:University of Nottingham | ||
Full Title: An open label trial of azithromycin in chronic productive cough | ||
Medical condition: The medical condition that will be investigated is that of chronic productive cough (with or without a diagnosis of asthma but without a diagnosis of bronchiectasis, smoking related chronic bronchi... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2011-003623-35 | Sponsor Protocol Number: CRS-02 | Start Date*: 2012-09-14 |
Sponsor Name:Bionorica SE | ||
Full Title: A multicentre, randomized, double-blind, placebo-controlled, parallel group study to assess efficacy and safety of two dosages of a herbal medicinal product (dry extract BNO 1016) in patients with ... | ||
Medical condition: Chronic Rhinosinusitis | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: PL (Completed) DE (Completed) CZ (Completed) BE (Completed) | ||
Trial results: View results |
EudraCT Number: 2021-002253-29 | Sponsor Protocol Number: CEC-11/NAS | Start Date*: 2022-03-08 | |||||||||||
Sponsor Name:Dr. Falk Pharma GmbH | |||||||||||||
Full Title: Double-blind, randomized, placebo-controlled, phase II dose-finding study comparing different doses of ZED1227 capsules with placebo in the treatment of non-alcoholic fatty liver disease (NAFLD) wi... | |||||||||||||
Medical condition: | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) PL (Completed) DE (Completed) BE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-002269-21 | Sponsor Protocol Number: 01.00240 | Start Date*: 2013-12-06 |
Sponsor Name:Department of Physiology and Cardiothoracic Surgery, Faculty of Medicine, University of Porto | ||
Full Title: Metformin in diastolic dysfunction of metabolic syndrome | ||
Medical condition: Diastolic dysfunction in non-diabetic patients with metabolic syndrome | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: PT (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2019-000307-32 | Sponsor Protocol Number: Repha_1439 | Start Date*: 2020-05-12 | |||||||||||
Sponsor Name:Repha GmbH | |||||||||||||
Full Title: Clinical trial for examination of efficacy and safety of MYRRHINIL-INTEST® versus placebo in patients with diarrhea-dominant irritable bowel syndrom (IBS-D) | |||||||||||||
Medical condition: Confirmed diagnosis of diarrhea-dominant irritable bowel syndrome (IBS-D) by a specialist physician and/or internal medicine and/or general medicine | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-000474-11 | Sponsor Protocol Number: 747-304 | Start Date*: 2018-12-07 | |||||||||||
Sponsor Name:Intercept Pharmaceuticals, Inc. | |||||||||||||
Full Title: A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Obeticholic Acid in Subjects with Compensated Cirrhosis due to Nonalcoholic Steatoh... | |||||||||||||
Medical condition: Compensated Cirrhosis due to Nonalcoholic Steatohepatitis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) ES (Ongoing) GB (GB - no longer in EU/EEA) HU (Completed) PL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-005030-15 | Sponsor Protocol Number: B1791094 | Start Date*: 2021-10-15 | |||||||||||
Sponsor Name:Pfizer Inc. | |||||||||||||
Full Title: AN EXPLORATORY, MULTICENTER, RANDOMIZED, DOUBLE BLIND STUDY OF CLINICAL OUTCOMES, TOLERABILITY, AND SAFETY OF 2 DOSES OF ORAL PANTOPRAZOLE IN PEDIATRIC PARTICIPANTS AGED 1 TO 11 YEARS AND 12 TO 17 ... | |||||||||||||
Medical condition: Erosive Esophagitis | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: SK (Trial now transitioned) BE (Trial now transitioned) HU (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-004374-15 | Sponsor Protocol Number: PUMA-NER-6201 | Start Date*: 2018-04-13 | |||||||||||
Sponsor Name:Puma Biotechnology, Inc. | |||||||||||||
Full Title: An Open Label Study to Characterize the Incidence and Severity of Diarrhea in Patients with Early Stage HER2+ Breast Cancer Treated with Neratinib and Intensive Loperamide Prophylaxis | |||||||||||||
Medical condition: Early Stage HER2+ Breast Cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) AT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-003248-63 | Sponsor Protocol Number: QBGJ398-302 | Start Date*: 2020-02-19 | |||||||||||
Sponsor Name:QED Therapeutics, Inc. | |||||||||||||
Full Title: Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial of Infigratinib for the Adjuvant Treatment of Subjects with Invasive Urothelial Carcinoma with Susceptible FGFR3 Genetic Alt... | |||||||||||||
Medical condition: Invasive Urothelial Carcinoma with Susceptible FGFR3 Genetic Alterations | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Prematurely Ended) DE (Completed) FR (Completed) BE (Completed) GB (GB - no longer in EU/EEA) NL (Completed) IT (Prematurely Ended) BG (Prematurely Ended) PT (Prematurely Ended) GR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-002572-39 | Sponsor Protocol Number: TargetFlame | Start Date*: 2022-03-30 | |||||||||||
Sponsor Name:Bezirkskliniken Schwaben | |||||||||||||
Full Title: Effects of add-on Celecoxib treatment in patients with schizophrenia spectrum disorders and inflammatory cytokine profile (TargetFlame) | |||||||||||||
Medical condition: Schizophrenia | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2022-004207-32 | Sponsor Protocol Number: TIKTAC-2-Trial | Start Date*: 2023-04-20 |
Sponsor Name:Medical University Innsbruck, Internal Medicine V | ||
Full Title: Daratumumab in combination with Carfilzomib, Pomalidomide and Dexamethasone (DCPD) in patients with multiple myeloma induced acute renal failure NOT requiring dialysis - “Time Is Kidney in the Trea... | ||
Medical condition: Multiple Myeloma: Patients with MM are frequently diagnosed primarily due to renal failure. Patients with renal failure have a poor prognosis. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: AT (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2016-004973-42 | Sponsor Protocol Number: 1289.32 | Start Date*: 2017-11-21 | |||||||||||
Sponsor Name:Boehringer Ingelheim Limited | |||||||||||||
Full Title: A phase II randomised, double-blind, placebo-controlled study to evaluate the efficacy, safety, and tolerability of orally administered BI 409306 during a 52-week treatment period as an early inter... | |||||||||||||
Medical condition: attenuated psychosis syndrome | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
